Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.
Sklavenitis-Pistofidis R, Lightbody ED, Reidy M, Tsuji J, Aranha MP, Heilpern-Mallory D, Huynh D, Chong SJF, Hackett L, Haradhvala NJ, Wu T, Su NK, Berrios B, Alberge JB, Dutta A, Davids MS, Papaioannou M, Getz G, Ghobrial IM, Manier S.
Sklavenitis-Pistofidis R, et al. Among authors: tsuji j.
bioRxiv [Preprint]. 2023 Aug 3:2023.08.01.551480. doi: 10.1101/2023.08.01.551480.
bioRxiv. 2023.
PMID: 37577538
Free PMC article.
Preprint.